U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
BOSTON, March 28, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:
| 1st Annual H.C. Wainwright & Company NASH Investor Conference | |
| Location: St. Regis New York in New York City (Versailles Room) | |
| Presentation date / time: Monday, April 3, 2017, at 11:00 a.m. ET | |
| Presenter: Paresh N. Soni, MD, PhD, Chief Medical Officer | |
| 16th Annual Needham Healthcare Conference | |
| Location: Westin Grand Central Hotel in New York City | |
| Presentation date / time: Tuesday, April 4, 2017, at 3:00 p.m. ET | |
| Presenter: Ron Cooper, President and Chief Executive Officer | |
A live audio webcast of the Needham conference presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
